In non-small-cell lung cancer, mutation of epidermal growth factor receptor (EGFR)
stimulates cell proliferation and survival. EGFR tyrosine kinase inhibitors (EGFR-TKIs) such …

The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR
tyrosine kinase inhibitors (EGFR‐TKIs) a milestone in the treatment for advanced non–small …

Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have a good
clinical efficacy in lung adenocarcinoma harboring activating-mutation EGFR. Such EGFR …

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI), is widely
applied as a first‑line treatment for non‑small cell lung cancer (NSCLC) and greatly improves …

Simple Summary This study investigated the relationship between erlotinib resistance and
stemness in lung adenocarcinoma. NCAPG2 was identified as an erlotinib resistance gene …

Gefitinib is a potent inhibitor of EGFR and represents the front-line treatment for non-small
cell lung cancer (NSCLC) therapeutics. However, NSCLC patients are prone to develop …

Therapies targeting the tyrosine kinase activity of Epidermal Growth Factor Receptor (EGFR)
have been proven to be effective in treating a subset of non-small cell lung cancer (NSCLC) …

The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung
cancer (NSCLC) has been shown to be effective in increasing patient progression free …

Background Lung cancer is the leading cause of cancer-related deaths. EGFR tyrosine
kinase inhibitors, such as erlotinib, were approved for non-small cell lung carcinoma …

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths
worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR‑TKIs) have …